Flaminia Pedretti

Flaminia Pedretti

Auto-generated profile, based on publicly available information

Flaminia Pedretti

Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2025 in Cancer Research
Verified
Journal Article
Closed access
FPFlaminia Pedretti
Flaminia Pedretti
Mohamed Abdel-FattahMohamed Abdel-Fattah
Mohamed Abdel-Fattah
BPBenedetta Pellegrino
Benedetta Pellegrino
FMFrancesca Mateo
Francesca Mateo
PSPaula Martinez Sanz
Paula Martinez Sanz
VSVioleta Serra
Violeta Serra
Homologous recombination deficiency (HRD) contributes to genomic instability and leads to sensitivity to PARP inhibitors (PARPi). HRD also activates the cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING)–interferon pathway, highlighting the need to understand the impact of cGAS–STING–IFN signaling on PARPi efficacy. In this study, we analyzed a cohort of 35 breast cancer patient-derived xenografts and mouse-derived allografts. PARPi sensitivity correlated with HRD, increased genomic instability, and activation of the cGAS–STING–IFN signaling pathway. Single-cell analyses showed that IFN signaling and IFN-based immune interactions were suppressed in preclinical models with acquired resistance to PARPi, lacking concomitant clonal expansion of functional CD8+ T cells. However, the combination of a PARPi and a novel STING agonist (STINGa) increased immune infiltration and resulted in superior antitumor activity in these tumors. Notably, the efficacy of PARPi monotherapy and the combination treatment with a STINGa was dependent on natural killer (NK) cells. In agreement, patients with breast cancer with BRCA1/BRCA2 mutations and good responses to PARPi showed higher abundancy of CD56+ NK cells in the tumor microenvironment and treatment-engaged CD56bright NK cells in the peripheral immune compartment, compared with those with poor responses. Therefore, these findings propose the combination of PARPis and a STINGa as a potential novel strategy to enhance the therapeutic response in patients with acquired PARPi resistance and highlight a pivotal role of NK cells in the PARPi antitumor activity. Significance: PARP inhibitor sensitivity is associated with cGAS–STING–IFN signaling, which can be harnessed by combining PARP inhibitors with STING agonists to overcome acquired resistance and requires NK cells to mediate antitumor immunity. See related commentary by Gohari et al., p. 1747

17 June 2026
Verified
Other
Open access
FPFlaminia Pedretti
Flaminia Pedretti
Mohamed Abdel-FattahMohamed Abdel-Fattah
Mohamed Abdel-Fattah
BPBenedetta Pellegrino
Benedetta Pellegrino
FMFrancesca Mateo
Francesca Mateo
PSPaula Martinez Sanz
Paula Martinez Sanz
VSVioleta Serra
Violeta Serra
Bulk RNA sequencing of Mouse Derived Allograft (MDA) tumors.

17 June 2026
Verified
Other
Open access
FPFlaminia Pedretti
Flaminia Pedretti
Mohamed Abdel-FattahMohamed Abdel-Fattah
Mohamed Abdel-Fattah
BPBenedetta Pellegrino
Benedetta Pellegrino
FMFrancesca Mateo
Francesca Mateo
PSPaula Martinez Sanz
Paula Martinez Sanz
VSVioleta Serra
Violeta Serra
Generation of PDX230OR8 and analysis of the mechanism of PARPi resistance

17 June 2026
Verified
Other
Open access
FPFlaminia Pedretti
Flaminia Pedretti
Mohamed Abdel-FattahMohamed Abdel-Fattah
Mohamed Abdel-Fattah
BPBenedetta Pellegrino
Benedetta Pellegrino
FMFrancesca Mateo
Francesca Mateo
PSPaula Martinez Sanz
Paula Martinez Sanz
VSVioleta Serra
Violeta Serra
Image analysis of tissue cyclic immunofluorescence in HRR-altered patients

17 June 2026
Verified
Other
Open access
FPFlaminia Pedretti
Flaminia Pedretti
Mohamed Abdel-FattahMohamed Abdel-Fattah
Mohamed Abdel-Fattah
BPBenedetta Pellegrino
Benedetta Pellegrino
FMFrancesca Mateo
Francesca Mateo
PSPaula Martinez Sanz
Paula Martinez Sanz
VSVioleta Serra
Violeta Serra
Combination of PARPi and STINGa in vivo

17 June 2026
Verified
Other
Open access
FPFlaminia Pedretti
Flaminia Pedretti
Mohamed Abdel-FattahMohamed Abdel-Fattah
Mohamed Abdel-Fattah
BPBenedetta Pellegrino
Benedetta Pellegrino
FMFrancesca Mateo
Francesca Mateo
PSPaula Martinez Sanz
Paula Martinez Sanz
VSVioleta Serra
Violeta Serra
Natural Killer (NK) cells depletion in vivo